Appendix 6—table 1. Baseline characteristics of female patients with MBC and COVID-19.
| MBC | |
|---|---|
| (N=233) | |
| Age, years† | |
| Median [IQR] | 58.0 [49.8, 68.3] |
| Race/ethnicity | |
| Non-Hispanic White | 107 (46%) |
| Non-Hispanic Black | 56 (24%) |
| Hispanic | 50 (21%) |
| Non-Hispanic AAPI | 10 (4%) |
| Other | 10 (4%) |
| Smoking status | |
| Never | 162 (70%) |
| Current or former | 66 (28%) |
| Missing/unknown | 5 (2%) |
| Obesity | |
| No | 139 (60%) |
| Yes | 93 (40%) |
| Comorbidities ‡ | |
| Cardiovascular | 42 (18%) |
| Pulmonary | 37 (16%) |
| Renal disease | 16 (7%) |
| Diabetes mellitus | 52 (22%) |
| Missing/unknown | 3 (1%) |
| ECOG performance status | |
| 0 | 63 (27%) |
| 1 | 84 (36%) |
| 2+ | 42 (18%) |
| Unknown | 44 (19%) |
| Missing | 0 (0%) |
| Receptor status | |
| HR+/HER2- | 98 (42%) |
| HR+/HER2+ | 53 (23%) |
| HR-/HER2+ | 26 (11%) |
| Triple negative | 33 (14%) |
| Missing/unknown | 23 (10%) |
| Cancer status | |
| Active and responding | 55 (24%) |
| Active and stable | 78 (33%) |
| Active and progressing | 74 (32%) |
| Unknown | 25 (11%) |
| Missing | 0 (0%) |
| Metastatic sites (MBC) | |
| Lung | 65 (28%) |
| Bone | 135 (58%) |
| Liver | 61 (26%) |
| Missing/unknown | 19 (8%) |
| Timing of anti-cancer therapy | |
| Never/after COVID-19 | X* |
| 0–4 weeks | 189 (81%) |
| 1–3 months | 14 (6%) |
| >3 months | 19 (8%) |
| Missing/unknown | 11 (5%)* |
| Modality of active anti-cancer therapy‡, § | |
| None | 24 (10%) |
| Cytotoxic chemotherapy | 114 (49%) |
| Targeted therapy | 115 (49%) |
| Endocrine therapy | 98 (42%) |
| Immunotherapy | 17 (7%) |
| Local (surgery/radiation) | 27 (12%) |
| Other | 6 (3%) |
| Missing/unknown | 6 (3%) |
| Region | |
| Northeast | 97 (42%) |
| Midwest | 44 (19%) |
| South | 34 (15%) |
| West | 56 (24%) |
| Undesignated | 2 (1%) |
| Period of COVID-19 diagnosis | |
| Jan-Apr 2020 | 33 (14%) |
| May-Aug 2020 | 101 (43%) |
| Sept-Dec 2020 | 52 (22%) |
| Jan-Aug 2021 | 45 (19%) |
| Missing/unknown | 2 (1%) |
| Area of patient residence | |
| Urban | 103 (44%) |
| Suburban | 80 (34%) |
| Rural | 12 (5%) |
| Missing/unknown | 38 (16%) |
| Treatment center characteristics | |
| Academic medical center | 43 (18%) |
| Community practice | 63 (27%) |
| Tertiary care center | 127 (55%) |
| Missing/unknown | 0 (0%) |
| Severity of COVID-19 | |
| Mild | 126 (54%) |
| Moderate | 93 (40%) |
| Severe | 13 (6%) |
| Missing/unknown | 1 (<1%) |
*
Cells combined to mask N<5 according to CCC19 low count policy.
†
Age was truncated at 90 years.
‡
Percentages could sum to >100% because categories are not mutually exclusive.
§
Within 3 months of COVID-19 diagnosis.